zorifertinib

Phase 1Small molecule

zorifertinib is one of 37 small molecule programs targeting Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentPhase 1

Recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

RC148

RRemeGen Co., Ltd.

Phase 3

1 3

Anktiva

SSWOG Cancer Research Network

Phase 3

1 4

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

NCT07361705

Q4 2031

Recruiting

Non-Small Cell Lung Cancer

NCT07143045

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Recruiting·AAlpha Biopharma (Jiangsu) Co., Ltd.··NCT07143045·800 enrolled

Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment1 trial

An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

Recruiting·AAlpha Biopharma (Jiangsu) Co., Ltd.·Phase 1·NCT07361705·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for zorifertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zorifertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zorifertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alpha Biopharma (Jiangsu) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAlpha Biopharma (Jiangsu) Co., Ltd.

zorifertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment1 trial

References

Drug Info

Quick Facts

Related News